CVS Health Corporation, the Woonsocket, Rhode Island-based healthcare and pharmacy giant, has been one of the market's more closely watched turnaround stories since the company ousted its previous chief executive in late 2024. After sliding toward the mid-$50s during that period, the stock has more than recovered, trading around $97 after touching a 52-week high of $110.68 in July. Against that backdrop, $120 has become a natural psychological milestone: it sits just above the average analyst price target near $116 and would mark a fresh multi-year peak.
CVS operates three interlocking businesses. Its Health Care Benefits segment, anchored by the Aetna insurance unit, provides medical plans including Medicare Advantage and Medicaid coverage. Health Services houses the Caremark PBM and the Oak Street Health primary-care clinics, while Pharmacy & Consumer Wellness runs roughly 9,000 retail locations. The integrated model is designed to manage medical and pharmacy costs together, which management argues creates revenue and cost synergies.
The stock's valuation reflects both its recovery and lingering skepticism. CVS carries a trailing P/E ratio in the mid-20s, above its five-year historical norm, yet it trades at a low price-to-sales multiple near 0.3 and offers a dividend yield of roughly 2.7%. With a market capitalization near $125 billion and a low beta, the shares behave more like a large-cap value holding than a high-growth name.
The clearest engine for a move toward $120 is the Medicare Advantage turnaround. In its second-quarter 2026 results, CVS posted adjusted earnings per share (EPS) of $2.58, well above consensus expectations, and raised its full-year adjusted EPS guidance to a range of $7.90 to $8.10. Management has also set a 2027 adjusted EPS floor of $8.44 and reiterated a mid-teens growth trajectory through 2028, with a target of roughly $9.50 per share by that year. Continued margin recovery in the healthcare benefits segment, disciplined pricing, and stronger cash flow would each support a higher valuation.
The risks are equally real. Higher-than-expected medical-cost utilization in Medicare Advantage has repeatedly pressured the sector, and CVS has flagged headwinds tied to the 340B drug-pricing program and membership declines at Caremark. Regulatory reform of PBMs remains an overhang, and GLP-1 rebate guarantees were cited by analysts as a potential threat to the margin story. A step back in utilization trends or a disappointing enrollment season could quickly erode the earnings recovery that underpins the bull case.
Wall Street's view is cautiously optimistic. The consensus rating is a "Strong Buy," with an average 12-month price target near $116, according to aggregator data, and individual estimates ranging from roughly $103 to as high as $148. That spread underscores genuine disagreement about how durable the turnaround will prove. A $120 objective sits slightly above the consensus, implying investors would need to see results that exceed the average analyst's base case.
From a technical analysis perspective, the $110.68 July high is the defining resistance level; a decisive breakout above it would likely be required before $120 becomes realistic. The $94–$97 range has served as near-term support following the stock's post-earnings pullback. Because $120 is a round psychological figure and a multi-year high, it represents both a supply zone and a sentiment threshold rather than a level the market is likely to clear casually.
Traders monitoring CVS's progress toward higher price targets can turn to Tickeron's AI Daily Buy/Sell Signals for additional context. This tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The signals are designed to help traders surface new opportunities, track existing positions, and identify changing market trends more efficiently than manual review alone. As CVS approaches key resistance levels, automated signal monitoring can offer a timely complement to traditional research.
A move to $120 for CVS Health is realistic over a multi-quarter horizon but far from guaranteed. The strongest support comes from an improving Medicare Advantage margin profile, raised guidance, and a management team that has committed to measurable earnings milestones. The primary risks are renewed medical-cost pressures, PBM regulatory uncertainty, and a valuation that already prices in meaningful improvement. Investors should monitor quarterly medical-loss-ratio trends, Medicare Advantage enrollment results, and whether the stock can clear its $110.68 high before reassessing the path to $120.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CVS has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CVS jumps, then UNH could also see price increases.